- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03665259
Lower Inspiratory Oxygen Fraction for Preoxygenation
Effects of Preoxygenation With Lower Inspiratory Oxygen Fraction During Induction of Anesthesia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The administration of 100% oxygen for 3-5 minutes may replace the nitrogen content in the lung cavity (de-nitrogenation) with higher alveolar concentrations of oxygen (greater then 95%). Elevation of oxygen reserve in the lung and oxygen partial pressure in the blood circulation may thus delay the development of hypoxemia (oxygen desaturation; defined as the tissue oxygen saturation below 90%) up to 10 minutes after apnea.
On the other hand, there is currently no clinical evidence indicating that preoxygenation with lower oxygen partial pressures (i.e. FiO2= 50-60%) during the induction of anesthesia increases the incidence of hypoxemia or other complications. Most recently, two elegant large-scale clinical trials reported that the supplement of oxygen to patients with acute myocardial infarction or acute ischemic stroke did not provide any clinically beneficial effects in the prognosis of diseases. The results of these two important trials did not support the routine supplement of oxygen in these acute diseases. In addition, high concentrations of oxygen therapy are potentially deleterious, as oxygen toxicity may result in direct tracheobronchial and alveolar damage, absorption atelectasis (lung tissue collapse) and central nervous system toxicity. In cellular levels, hyperoxia increases the production of reactive oxygen species, such as the superoxide anion, the hydroxyl radical, and hydrogen peroxide, which in turn may cause cellular apoptosis and inflammatory response. Therefore, oxygen therapy in clinical settings has been recognized as a two-edged sword and excessive oxygen supplement should be guided closely for its potential toxicity.
Currently, there is no clinical evidence that supports the routine administration of 100% oxygen prior to intubation is essential or beneficial. In the contrary, it also remains undetermined if lower fractions of inspiratory oxygen during the induction period of anesthesia may attenuate lung injury or other cellular damage derived from the oxygen toxicity. Therefore, the findings of this proposed clinical study may provide fundamental evidence for the use of different oxygen concentrations in clinical anesthesia during the induction period, and determine the effects of inspiratory oxygen concentrations on the general postoperative outcomes after general anesthesia.
This is a randomized, open-label, observer-blind and non-inferiority clinical trial.
The research model of study is two-group parallel interventional study. The control group is preoxygenation with 100% oxygen during the induction phase of anesthesia; the experimental group is preoxygenation with 60% oxygen during the induction phase of anesthesia. The anesthetists in-charge are not blinded to the concentrations of oxygen use during induction of anesthesia, but the persons who collected study data will be unaware of the treatment. Block randomization will be generated using a generator software and the assignment of treatment will be sealed in the envelops.
This study anticipates in enrolling 1500 participants.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kaohsiung
-
Yanchao, Kaohsiung, Taiwan, 824
- E-DA Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A patient who is scheduled for an elective surgery and required for general anesthesia with endotracheal intubation.
- Age of the patient is between 20 and 65 years old.
- Patient's American Society of Anesthesiologists (ASA) Physical Status is I- III.
Exclusion Criteria:
Patients who:
- Have difficult airway for ventilation or intubation.
- Have severe lung disease (including any acute respiratory infection).
- Had past history of coronary artery disease or myocardial infarction.
- Have severe heart failure (NYHA Fc ≥III).
- Have liver cirrhosis (Child-Pugh's score ≥B).
- Have acute or chronic kidney disease (Creatinine ≥2 mg/dl).
- Have severe anemia (hemoglobin ≤8 mg /dl).
- Have a body mass index (BMI) ≥35.
- Are currently pregnant.
- Have inadequate fasting time, intestinal obstruction or severe gastroesophageal reflux.
- Scheduled for an emergency surgery, cardiac surgery, craniotomy, or pulmonary surgery.
- Have mental incapacitant, confusion, dementia, mental retardation, or are unable to complete the consent independently.
- Refuse to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pure oxygen group
The patients receive 100% oxygen therapy during the induction phase of induction
|
pre-oxygenation with 100% oxygen during induction of anesthesia
|
Experimental: Lower oxygen group
The patients received 60% oxygen therapy during the induction phase of induction
|
Pre-oxygenation with 60% oxygen during induction of anesthesia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of hypoxemia
Time Frame: Within 30 minutes after induction of anesthesia
|
The definition of hypoxemia is the measurement of peripheral oxygen saturation (sPO2) lower than < 92%.
Induction phase of anesthesia is defined as the time frame from preoxygenation before intravenous administration of anesthetics to successful establishment of an endotracheal tube.
|
Within 30 minutes after induction of anesthesia
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of acute respiratory distress syndrome (ARDS)
Time Frame: Within 7 days after surgery
|
ARDS is defined as any calculated PaO2/FiO2 less than 300mmHg with radiographic evidence of bilateral lung infiltration in the absence of left heart failure
|
Within 7 days after surgery
|
Development of atelectasis
Time Frame: Within 7 days after surgery
|
Atelectasis is defined as partial or complete collapse of lung lobe(s) on chest radiography
|
Within 7 days after surgery
|
Development of pneumonia
Time Frame: Within 7 days after surgery
|
Pneumonia is defined as acute infection of lung parenchyma
|
Within 7 days after surgery
|
Development of surgical site infection (SSI)
Time Frame: Within 7 days after surgery
|
SSI is defined as infection arising from surgical incision
|
Within 7 days after surgery
|
Development of severe postoperative pain
Time Frame: Within 7 days after surgery
|
Severe postoperative pain is defined as visual analogue scale (VAS) >4 despite of administration of analgesics.
VAS is defined as a straight line with the endpoints representing the extreme limits of pain; "no pain at all= 0" and "pain as bad as it could be= 10"
|
Within 7 days after surgery
|
Length of hospital stay (LOS)
Time Frame: Within 7 days after surgery
|
LOS is defined as day(s) of hospitalization after surgery
|
Within 7 days after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chen-Fuh Lam, MD, PhD, E-DA Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMRP15107N
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oxygen Deficiency
-
Oxfo CorporationCompletedOxygen Deficiency | Oxygen TherapyColombia
-
Hannibal TroensegaardCompletedOxygen Deficiency | Oxygen ToxicityDenmark
-
Inonu UniversityCompletedSmoking | Oxygen Deficiencies
-
Marmara UniversityCompleted
-
Masimo CorporationUniversity Medical Center GroningenCompleted
-
Medical University InnsbruckCompletedOxygen DeficiencyAustria
-
Nantes University HospitalUnknown
-
Medtronic - MITGCompleted
-
University of Novi Sad, Faculty of Sport and Physical...Completed
Clinical Trials on Pure oxygen group
-
Cliniques universitaires Saint-Luc- Université...WithdrawnHealthy | Coronary Artery Bypass GraftBelgium
-
University of AlbertaCanadian Institutes of Health Research (CIHR)RecruitingSpinal Cord InjuriesCanada
-
Glostrup University Hospital, CopenhagenUnknownHealthy Individuals | Patients With Diabetes.Denmark
-
Association Nationale pour les Traitements A Domicile...RecruitingLUNG DISEASES, OBSTRUCTIVEFrance
-
University Hospital, MontpellierCompletedObesity | Ventilation | Intensive Care UnitFrance
-
Qinghai UniversityCompleted
-
Jiuda ZhaoRecruiting
-
Dr. David Yuen Chung CHANRecruitingChronic Subdural HematomaHong Kong
-
Western Regional Medical CenterWithdrawnCancer Cachexia
-
University of AlbertaUniversity of Manitoba; University of British Columbia; McGill University; McMaster... and other collaboratorsRecruitingPremature Infant | Respiratory Distress Syndrome in Premature Infant | Neurodevelopmental OutcomeCanada, Ireland, Spain